News

The pharmaceutical company has also adopted OneKey, the globally comprehensive healthcare professional (HCP) database, and Analyzer for dynamic reporting and actionable analytics. Cegedim’s Mobile Intelligence is believed to

According to the company, the joint solutions are expected to simplify and accelerate the use of new-genermaration mass spectrometry technologies. As per the collaboration, AB SCIEX is combining

Ibudilast demonstrated significant efficacy in a model of post-TBI anxiety, one of the most common disorders caused by TBI. A short course of systemic ibudilast administered over a

The objectives of double-blinded, randomized trial, are to assess the efficacy, local tolerability and safety of DPK-060 ear drops in infections caused by bacterial or fungal pathogens. The

Nobelpharma developed Fostoin in Japan. It will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement. Fostoin is a water-soluble prodrug of

According to the company, the restructuring will strengthen its competitive position in light of loss of Diovan patent and announces charge for Rasilez/Tekturna. The US General Medicines restructuring

The companies will end their co-development and co-promotion agreement for certolizumab pegol in Japan followed by an agreed upon transition period. UCB plans to further develop its immunology

Rotigotine Patch has been developed as a treatment for Parkinson’s disease and restless legs syndrome. The patch will provide a continuous release of the drug substance and maintains

Under the agreement Mitsubishi is responsible for any necessary development and regulatory approval costs, pay undisclosed upfront, pre-commercial milestones and pay Nuron significant royalties on commercial sales in